Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO

To verify whether the intensification of the upfront chemotherapy backbone with a modified schedule of modified fluorouracil, leucovorin, oxaliplatin, and irinotecan (mFOLFOXIRI) increases the activity of fluorouracil, leucovorin, and oxaliplatin when both regimens are combined with panitumumab as i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossini, Daniele, Antoniotti, Carlotta, Lonardi, Sara, Pietrantonio, Filippo, Moretto, Roberto, Antonuzzo, Lorenzo, Boccaccino, Alessandra, Morano, Federica, Brugia, Marco, Pozzo, Carmelo, Marmorino, Federica, Bergamo, Francesca, Tamburini, Emiliano, Passardi, Alessandro, Randon, Giovanni, Murgioni, Sabina, Borelli, Beatrice, Buonadonna, Angela, Giordano, Mirella, Fontanini, Gabriella, Conca, Veronica, Formica, Vincenzo, Aglietta, Massimo, Bordonaro, Roberto, Aprile, Giuseppe, Masi, Gianluca, Boni, Luca, Cremolini, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426812/
https://www.ncbi.nlm.nih.gov/pubmed/35666229
http://dx.doi.org/10.1200/JCO.22.00839

Ejemplares similares

Ejemplares similares